-- BPT567 is the first bifunctional PD1-IL18 immunoconjugate to enter clinical development -- -- Phase 1/2a study will evaluate BPT567…
Projections for Pharmaloz Manufacturing: Approximately $16-17 Million in Revenue, $6-7 Million in Pre-Tax Earnings for 2025 Strategic Partnership Discussions Begin for…
CAMBRIDGE, Mass., Oct. 17, 2024 (GLOBE NEWSWIRE) -- Eterna Therapeutics Inc. (Nasdaq: ERNA) (“Eterna” or the “Company”) and Factor Bioscience…
First payment received under Tonix’s contract with the Defense Threat Reduction Agency (DTRA), for up to $34 million over five…
Media Release First safety data anticipated before year end with assessment of PK/PD relationships to follow in H1’CY2025 SYDNEY, AUSTRALIA,…
WARREN, N.J., Oct. 17, 2024 (GLOBE NEWSWIRE) -- HMP Partners and The Patel Family LLP, leading investors in innovative healthcare…
Part A of the placebo-controlled Phase 2 study has been completed ANAVEX®3-71 demonstrates a dose-dependent pharmacodynamic effect on objective EEG…
Avacta Group plc ("Avacta" or "the Group" or "the Company")Avacta Expands its Pipeline with Two Novel Assets Developed Using its…
VALENCIA, Calif. and TEL AVIV, Israel, Oct. 17, 2024 (GLOBE NEWSWIRE) -- Nusano, a physics company transforming the production of…
• Barrigel™ rectal spacer provides high quality rectal spacing, enabling low dose to the rectum during prostate cancer radiation therapy,…